newsfilter
← Latest News
GlobeNewswire·

Kronos Bio Reports First-Quarter 2024 Financial Results

— $152.0 million cash runway into the second half of 2026 — — A study update on KB-0742-1001 will be presented at the upcoming American Society of Clinical Oncology (ASCO); expansion cohorts at new dose schedule